May 25, 2016 – DUBLIN–(BUSINESS WIRE)–Regulatory News: Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), today announced that it has received CE Mark approval for ReActiv8®, its innovative and proprietary implantable neurostimulation system to treat disabling chronic low back pain. CE Marking enables commercialization of ReActiv8 in Europe. The […]

Share on LinkedInShare on FacebookShare on Google+Pin on PinterestEmail this to someone